Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and sirolimus may also stop the growth of liver cancer by blocking blood flow to the tumor. Giving sirolimus together with bevacizumab may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus when given together with bevacizumab in treating patients with liver cancer that cannot be removed by surgery.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Cancer Centre, Singapore
• Treatments: Bevacizumab; Everolimus; Sirolimus

Criteria

DISEASE CHARACTERISTICS:

• Meets 1 of the following criteria:

• Histologically confirmed unresectable hepatocellular carcinoma, meeting all of the following criteria:

• Failed 0-2 lines of chemotherapy

• Child-Pugh class A or B for liver cirrhosis

• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with conventional techniques or ≥ 10 mm with spiral CT scan

• No known brain metastases

• Bone metastases allowed provided other measurable disease is present

• Healthy participant

PATIENT CHARACTERISTICS:

• ECOG performance status (PS) 0-2 or Karnofsky PS 70-100%

• Life expectancy > 3 months

• WBC ≥ 3,000/mm³

• Absolute neutrophil count ≥ 1,500/mm³

• Platelet count ≥ 100,000/mm³

• Bilirubin ≤ 3 times upper limit of normal (ULN)

• AST and ALT ≤ 5 times ULN

• Creatinine normal

• PTT < 1.5 times ULN

• Fasting serum cholesterol ≤ 350 mg/dL

• Triglycerides ≤ 300 mg/dL

• Proteinuria < 2+ by urine dipstick OR urine protein ≤ 1 g by 24-hour urine collection

• No history of allergic reactions to compounds of similar chemical or biologic composition to sirolimus or bevacizumab

• No prior thromboembolic disease that may result in bleeding or clotting problems related to use of bevacizumab including, but not limited to, the following:

• Esophageal varices

• Bleeding disorders

• Deep vein thromboses

• No history of hematemesis or hemoptysis

• No other uncontrolled illness including, but not limited to, the following:

• Ongoing or active infection

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Cardiac arrhythmia

• Psychiatric illness or social situations that would preclude study participation

• No HIV positivity

• Able to take oral medications

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception prior to and during the course of study treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• More than 28 days since prior surgery and recovered

• No other concurrent investigational agents

• No other concurrent anticancer therapy

• No concurrent traditional Chinese medicine(s)

• No concurrent long term anticoagulation with heparin or warfarin

• Concurrent prophylactic low-dose acetylsalicylic acid for patients at risk of an arterial thromboembolic event allowed

• Hepatitis B carriers must be on lamivudine during and for 6 months after completion of study treatment